A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Clinical trial NCT01714739 · COMPLETED
Trial details
- NCT number
- NCT01714739
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-10-07
- Primary completion
- 2019-12-13
- Enrollment
- 337
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.